Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
Danila SeidelMichaela SimonRosanne SpruteMatthias LubnowKatja EvertClaudius SpeerJessica SeeßleElham KhatamzasUta MerleChristopher BehrensIgor Wolfgang BlauPhilipp EnghardChristian S HaasJoerg SteinmannOliver KurzaiOliver Andreas CornelyPublished in: Mycoses (2021)
COVID-19-associated mucormycosis is rare in Germany, mostly reported in patients with comorbidities and impaired immune system and severe COVID-19 treated in the ICU with high mortality compared to mainly rhino-orbito-cerebral CAM in patients with mild COVID-19 in India. Risk for CAM is higher in hospitalised COVID-19 patients than in other patients.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- peritoneal dialysis
- intensive care unit
- cardiovascular disease
- type diabetes
- cardiovascular events
- coronary artery disease
- patient reported outcomes
- early onset
- brain injury
- blood brain barrier
- extracorporeal membrane oxygenation
- patient reported
- community acquired pneumonia
- breast cancer risk